Selection of desmopressin preparations for the treatment of central diabetes insipidus
https://doi.org/10.14341/omet2017423-30
Abstract
Central diabetes insipidus (CDI) is a severe pathology of the hypothalamic-pituitary system, based on a deficit of antidiuretic hormone (ADH). The disease is a life threating condition for patients without adequate replacement therapy by various preparations of arginine vasopressin. This review presents the current concepts on etiology, pathogenesis, diagnostic proсedures, and treatment of CDI. The article gives comparative pharmacological characteristics of various desmopressin forms for the treatment of the central form of disease. When choosing a therapy for the treatment of CDI, the article highlights the long-term high efficiency and safety of the original sublingual form of desmopressin (Mininin Melt), which is confirmed by real clinical practice and clinical trials, including the comparison with other forms of desmopressin.
About the Author
Elena V. BiryukovaMoscow State University of Medicine and Dentistry named after A.I. Evdokimov
Russian Federation
ScD
References
1. Мазеркина Н.А. Минирин для сублингвального применения в терапии несахарного диабета у больных после хирургического лечения опухолей мозга // Проблемы эндокринологии. — 2012. — Т.58. — №5. — С. 46-49. [Mazerkina NA. Minirin for the sublingual application to manage diabetes insipidus in the patients treated for brain tumours. Problems of Endocrinology. 2012;58(5):46-49. (In Russ).] doi: 10.14341/probl201258546-49.
2. Наточин Ю. В., Мухин Н. А. Введение в нефрологию — М.: ГЭОТАР–Медиа, 2007. [Natochin YuV, Mukhin NA. Vvedenie v nefrologiyu — Moscow: GEOTAR–Media; 2007. (In Russ).]
3. Пигарова Е.А., Дзеранова Л.К. Диагностика и лечение центрального несахарного диабета. // Ожирение и метаболизм. — 2014. — Т.11. — №4. — С. 48-55. [Pigarova EA, Dzeranova LK. Diagnosis and treatment of central diab etes insipidus. Obesity and metabolism. 2014;11(4):48-55. (In Russ).] doi: 10.14341/omet2014448-55.
4. Смирнов В.В., Мавричева И.С. Несахарный диабет у детей // Лечащий врач.—2005. — №8. — С. 42—47. [Smirnov VV, Mavricheva IS. Nesakharnyi diabet u detei. Lechaschi Vrach. 2005; (8):42-47. (In Russ).]
5. Arima H, Oiso Y, Juul KV, et al. Efficacy and safety of desmopressin orally disintegrating tablet in patients with central diabetes insipidus: results of a multicenter open-label dose-titration study. Endocr J. 2013;60(9):1085-1094. doi: 10.1507/endocrj.EJ13-0165.
6. Aoyagi T, Koshimizu T-a, Tanoue A. Vasopressin regulation of blood pressure and volume: findings from V1a receptor–deficient mice. Kidney Int. 2009;76(10):1035-1039. doi: 10.1038/ki.2009.319.
7. Baylis PH, Cheetham T. Diabetes insipidus. Arch Dis Child. 1998;79(1):84-89. doi: 10.1136/adc.79.1.84.
8. Baylis PH, Thompson CJ. Osmoregulation of Vasopressin Secretion and Thirst in Health and Disease. Clin Endocrinol (Oxf). 1988;29(5):549-576. doi: 10.1111/j.1365-2265.1988.tb03704.x.
9. Ball S. Vasopressin and disorders of water balance: the physiology and pathophysiology of vasopressin. Ann Clin Biochem. 2007;44(5):417-431.
10. Carraro A, Fano M, Porcella E, et al. [Treatment of central diabetes insipidus using oral DDAVP. Comparison with intranasal treatment]. Minerva Endocrinol. 1991;16(3):141-145.
11. Carraro A, Fano M, Cuttica M, et al. [Long-term treatment of central diabetes insipidus with oral DDAVP]. Minerva Endocrinol. 1992;17(4):189-193.
12. Ferring Pharmaceuticals. Absolute Bioavailability of three different doses of desmopressin in an orodispersible tablet in healthy non-smoking male volunteers. Clinical Study Report FE992026 CS004; 25 June 2002
13. Lottmann H, Froeling F, Alloussi S, et al. A randomised comparison of oral desmopressin lyophilisate (MELT) and tablet formulations in children and adolescents with primary nocturnal enuresis. Int J Clin Pract. 2007;61(9):1454-1460. doi: 10.1111/j.1742-1241.2007.01493.x.
14. Gelli D, Riolo A, Carioni E, Albano M. [Clinical evaluation of 2 new formulations of desmopressin (DDAVP), nasal spray and tablets, in the therapy of diabetes insipidus]. Minerva Endocrinol. 1989;14(4):227-232.
15. Juul KV, Erichsen L, Robertson GL. Temporal delays and individual variation in antidiuretic response to desmopressin. AJP: Renal Physiology. 2012;304(3):F268-F278. doi: 10.1152/ajprenal.00502.2012.
16. Juul KV, Schroeder M, Rittig S, Nørgaard JP. National Surveillance of Central Diabetes Insipidus (CDI) in Denmark: Results From 5 Years Registration of 9309 Prescriptions of Desmopressin to 1285 CDI Patients. J Clin Endocr Metab. 2014;99(6):2181-2187. doi: 10.1210/jc.2013-4411.
17. Kim RJ, Malattia C, Allen M, et al. Vasopressin and desmopressin in central diabetes insipidus: adverse effects and clinical considerations. Pediatr Endocrinol Rev. 2004;2 Suppl 1:115-123.
18. Knepper MA, Ingelfinger JR, Kwon T-H, Nielsen S. Molecular Physiology of Water Balance. N Engl J Med. 2015;372(14):1349-1358. doi: 10.1056/NEJMra1404726.
19. Laczi F. [Diabetes insipidus: etiology, diagnosis, and therapy]. Orv Hetil. 2002;143(46):2579-2585.
20. Maghnie M. Diabetes insipidus. Horm Res Paediatr. 2003;59(1):42-54. doi: 10.1159/000067844.
21. Nemergut EC, Zuo Z, Jane JA, Laws ER. Predictors of diabetes insipidus after transsphenoidal surgery: a review of 881 patients. J Neurosurg. 2005;103(3):448-454. doi: 10.3171/jns.2005.103.3.0448.
22. Nielsen S, Frøkiær J, Marples D, et al. Aquaporins in the Kidney: From Molecules to Medicine. Physiol Rev. 2002;82(1):205-244. doi: 10.1152/physrev.00024.2001.
23. Østerberg O, Savic RM, Karlsson MO, et al. Pharmacokinetics of Desmopressin Administrated as an Oral Lyophilisate Dosage Form in Children With Primary Nocturnal Enuresis and Healthy Adults. The Journal of Clinical Pharmacology. 2006;46(10):1204-1211. doi: 10.1177/0091270006291838.
24. Østerberg O, Balchen T, Riis A, Senderovitz T. G78 Pharmacokinetics Of Desmopressin In Children And Adults Using A New Oral Lyophilisate. Arch Dis Child. 2006;91:A33.
25. Prager-Khoutorsky M, Bourque CW. Osmosensation in vasopressin neurons: changing actin density to optimize function. Trends Neurosci. 2010;33(2):76-83. doi: 10.1016/j.tins.2009.11.004.
26. Robinson AG, Verbalis JG. The posterior pituitary. In Williams Textbook of Endocrinology; Philadelphia, 2003: WB Saunders; 281-329.
27. Robertson GL. Thirst and vasopressin function in normal and disordered states of water balance. Translational Research. 1983;101(3):351-371.
28. Saborio P, Tipton GA, Chan JCM. Diabetes Insipidus. Pediatr Rev. 2000;21(4):122-129. doi: 10.1542/pir.21-4-122.
29. Samarasinghe S, Vokes T. Diabetes insipidus. Expert Rev Anticancer Ther. 2014;6(sup1):S63-S74. doi: 10.1586/14737140.6.9s.S63.
30. Tien R, Kucharczyk J, Kucharczyk W. MR imaging of the brain in patients with diabetes insipidus. Am J Neuroradiol. 1991;12(3):533-542.
31. Tian Y. Downregulation of renal vasopressin V2 receptor and aquaporin-2 expression parallels age-associated defects in urine concentration. AJP: Renal Physiology. 2004;287(4):F797-F805. doi: 10.1152/ajprenal.00403.2003.
32. Vande Walle J, Stockner M, Raes A, Norgaard J. Desmopressin 30 Years in Clinical Use: A Safety Review. Current Drug Safety. 2007;2(3):232-238. doi: 10.2174/157488607781668891.
33. Verbalis JG. Reviews in Endocrine and Metabolic Disorders. 2003;4(2):177-185. doi: 10.1023/a:1022946220908.
Supplementary files
|
|
1. Рис. 1. Механизм действия АВП на уровне почечных канальцев. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(525KB)
|
Indexing metadata ▾ | |
|
|
2. Рис. 2. Причины центрального несахарного диабета (ЦНД) | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(160KB)
|
Indexing metadata ▾ | |
|
|
3. Рис. 3. Структура вазопрессина и десмопрессина. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(119KB)
|
Indexing metadata ▾ | |
Review
For citations:
Biryukova E.V. Selection of desmopressin preparations for the treatment of central diabetes insipidus. Obesity and metabolism. 2017;14(4):23-30. (In Russ.) https://doi.org/10.14341/omet2017423-30
Views:
9752
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
